FDA Inspection
Niagara Pharmaceuticals IncNiagara Pharmaceuticals Inc – FDA Inspection, Apr 25, 2022
Record Details
This FDA Inspection record concerns Niagara Pharmaceuticals Inc, with an inspection on April 25, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Niagara Pharmaceuticals Inc
- Inspection Date
- April 25, 2022
- Product Type
- Drugs
View Company Profile
ID · ab045d3c-45f7-4c1d-86c2-6d21f4cb8a72
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1167881
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
4- 21 CFR 211.103Actual vs. theoretical yields not determined
- 21 CFR 211.84(b)Representative Samples Criteria
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.100(a)Approval and review of procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Niagara Pharmaceuticals Inc
5| Date | Classification | Office | Project area |
|---|---|---|---|
| February 7, 2020 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 18, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 16, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 14, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 8, 2010 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Niagara Pharmaceuticals Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.